Regensburg, Germany, and Oxford, UK, 28 March 2017 – Fast-growing innovative diagnostics company numares AG and Oxford University are collaborating to develop an in-vitro diagnostic (IVD) test to improve therapeutic decision making for patients with multiple sclerosis (MS). The foundation for test development is based on published research conducted at Oxford to differentiate MS patients by metabolic biomarkers using nuclear magnetic resonance spectra. numares will provide its Magnetic Group Signaling® (MGS®) technology at Oxford to enable researchers to rapidly advance their research toward the creation of a non-invasive diagnostic test.
